Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-response relationship between light exposure and cycling performance.
Knaier R, Meister S, Aeschbacher T, Gemperle D, Rossmeissl A, Cajochen C, Schmidt-Trucksäss A. Knaier R, et al. Among authors: aeschbacher t. Scand J Med Sci Sports. 2016 Jul;26(7):794-801. doi: 10.1111/sms.12535. Epub 2015 Aug 14. Scand J Med Sci Sports. 2016. PMID: 26271769 Clinical Trial.
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV.
Mateo R, Xu S, Shornikov A, Yazdi T, Liu Y, May L, Han B, Han D, Martin R, Manhas S, Richards C, Marceau C, Aeschbacher T, Chang S, Manuilov D, Hollnberger J, Urban S, Asselah T, Abdurakhmanov D, Lampertico P, Maiorova E, Mo H. Mateo R, et al. Among authors: aeschbacher t. JHEP Rep. 2023 Aug 22;5(11):100893. doi: 10.1016/j.jhepr.2023.100893. eCollection 2023 Nov. JHEP Rep. 2023. PMID: 37929228 Free PMC article.
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Hollnberger J, Liu Y, Xu S, Chang S, Martin R, Manhas S, Aeschbacher T, Han B, Yazdi T, May L, Han D, Shornikov A, Flaherty J, Manuilov D, Suri V, Asselah T, Lampertico P, Wedemeyer H, Aleman S, Richards C, Mateo R, Maiorova E, Cihlar T, Mo H, Urban S. Hollnberger J, et al. Among authors: aeschbacher t. J Hepatol. 2023 Sep;79(3):657-665. doi: 10.1016/j.jhep.2023.04.027. Epub 2023 Apr 27. J Hepatol. 2023. PMID: 37120031 Clinical Trial.
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B.
Wagner J, Yuen L, Littlejohn M, Sozzi V, Jackson K, Martin R, Aeschbacher T, Suri V, Tan SK, Feierbach B, Gaggar A, Marcellin P, Buti Ferret M, Janssen HLA, Gane E, Meagher N, Price DJ, Wong D, Thompson AT, Revill PA. Wagner J, et al. Among authors: aeschbacher t. Aliment Pharmacol Ther. 2023 Mar;57(5):509-523. doi: 10.1111/apt.17299. Epub 2022 Nov 25. Aliment Pharmacol Ther. 2023. PMID: 36427857
Establishment and Characterization of an HBV Viral Spread and Infectious System following Long-Term Passage of an HBV Clinical Isolate in the Primary Human Hepatocyte and Fibroblast Coculture System.
Liu Y, Kornyeyev D, May L, Han D, Aeschbacher T, Chang S, Martin R, Mo H, Feierbach B. Liu Y, et al. Among authors: aeschbacher t. J Virol. 2022 Sep 28;96(18):e0084922. doi: 10.1128/jvi.00849-22. Epub 2022 Aug 29. J Virol. 2022. PMID: 36037476 Free PMC article.